Navigation Links
PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences
Date:12/2/2013

edy and award of attorney's fees and expert witness costs in light of the Supreme Court's opinion. For more information about PharmAthene, please visit www.PharmAthene.com.

Forward-Looking Statements

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "will," "hopeful," "designed," "expect," "objective" or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements, except as required by law. Forward-looking statements include known and unknown risks and uncertainties, including, among others, the impact of the termination of the merger agreement between Pharmathene and Theraclone, including litigation previously announced relating to the proposed merger the Company's need for and ability to obtain additional financing; risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs; the award of government contracts to competitors; unforeseen safety issues; unexpected determinations that these product candidates prove not to be effective or capable of being marketed as products; as well as risks detailed from time to time in PharmAthene's annual report on Form 10-K and quarterly reports on Form 10-Q under the caption "Risk
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
2. PharmAthene to Host Second Quarter 2013 Conference Call and Webcast on Wednesday, August 7, 2013
3. PharmAthene To Host First Quarter 2013 Conference Call And Webcast On Wednesday, May 8, 2013
4. PharmAthene Reports Year-End 2012 Financial And Operational Results
5. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
6. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
7. PharmAthene Reports Third Quarter 2012 Financial Results
8. PharmAthene Reports First Quarter 2012 Financial Results
9. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
10. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
11. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 WriteResult®, a leading ... that it has expanded its myPROpad™ ePRO tablet with ... one of the most widely used and well-respected ... health status. The EQ-5D is used during clinical trials ... measure that can be used to demonstrate Health-Related Quality ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets ... Supplies - Global Strategic Business Report" report to their offering. ... and Tissue Culture Supplies in US$ Thousands by the following Product ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Latin America . Annual ...
(Date:8/19/2014)... Robin Williams’ passing is a sad reminder ... individual. Symptoms range from slowness of voluntary movements ... severe depression. Parkinson’s disease progressively gets worse over ... neurons of the brain. As these patients struggle ... progressively gets worse, they look for options. ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated ... in a new PSUR – responding to the increasing need ... a drug. Adopted in many regions, the main objectives of ... comprehensive and critical analysis of new or emerging information on ... new evidence of the potential benefits of a drug; and ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... a new platform-independent Java client API for exchanging files ... HTTPS encrypted connections. , ,MOVEit API Java will supplement ... Windows API and a Perl API for Unix systems, ... ,The Java offering is targeted at mainframe, Solaris, Linux ...
... There are three locations on an Internet search page: top, ... a single page and other times its 100 feet long. ... sites identity is successful, only then will it will float ... if its submerged like a submarine, it will stay caught ...
... put his Ph.D. in theoretical physics to use not in ... affairs officer for the National Science Foundation . , ... residence for the week, he presented a public lecture ... Weapon, at which he discussed the relationship between writing science ...
Cached Biology Technology:Does your web site have visibility? 2Does your web site have visibility? 3NSF officer speaks on the future of journalism and science 2NSF officer speaks on the future of journalism and science 3
(Date:8/19/2014)... many parts of the world, leprosy and tuberculosis ... cases of leprosy per year, with nearly all ... currently available century-old vaccine Bacille Calmette-Guerin, or BCG, ... leprosy, so a more potent vaccine is needed ... found a stronger weapon against both diseases., In ...
(Date:8/19/2014)... (Boston) Some infants born with neonatal abstinence ... a more difficult time going through withdrawal than ... understood. While genetic and epigenetic (when genes are ... identified as potential factors, researchers at Boston University ... (BMC) conducted a first of its kind study ...
(Date:8/19/2014)... University of Texas Health Science Center at San Antonio ... today announced the awarding of more than $750,000 in ... Innovation Challenge. , Launched in 2003, SALSI is a ... an academic health science center join forces for greater ... collaborative studies, with a focus on public health issues ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3
... of developing bipolar disorder depends in part on the combined, ... the brain, none of which is powerful enough to cause ... targeting the enzyme produced by one of these genes could ... research was conducted by scientists at the National Institutes of ...
... studied the molecular basis of memory storage, trying to ... stores genetic memory. In an important study published this ... report for the first time that memory storage can ... rat hippocampus by manipulating a so-called "memory molecule," a ...
... for their effects on fat development, researchers have discovered ... in mice without some of the side effects attributed ... as harmine, was first isolated more than 150 years ... preparations around the world, the team reports in the ...
Cached Biology News:Genetic roots of bipolar disorder revealed by first genome-wide study of illness 2Genetic roots of bipolar disorder revealed by first genome-wide study of illness 3New Brandeis research sheds light on memory by erasing it 2Fat screen delivers plant-derived chemical with antidiabetic effects 2
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Biology Products: